Investors & Media

Eplontersen Phase 3 results published in JAMA show consistent and sustained benefit

Publication of NEURO-TTRansform study in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) showed eplontersen halted disease progression and continuously improved quality of life at 35-, 66- and 85-week analyses Data demonstrates consistent and sustained benefit on

Read more
You are now leaving to visit